ArticlePLOS digital health2026
Short-term prediction of COPD exacerbations based on wearable vital sign monitoring.
Article in PLOS digital health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04963192 (Integrated Management of Chronic Respiratory Diseases - eMEUSE-SANTE), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Integrated Management of Chronic Respiratory Diseases - eMEUSE-SANTE
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Early detection of acute exacerbations of chronic obstructive pulmonary disease (AECOPD) remains a critical challenge in COPD management. This study introduces the Bora Vital Sign Standard Score (BVS3), a novel unsupervised statistical score that predicts AECOPD using vital signs collected at home through remote patient monitoring, and retrospectively evaluates its predictive performance in identifying AECOPD ahead of clinician-defined episodes. The eMEUSE-SANTÉ clinical trial (NCT04963192) involved 220 COPD patients who were remotely monitored for six months using a CE-certified (Class IIa) connected wristband measuring oxygen saturation (SpO₂), breathing rate (BR) and heart rate (HR). A total of 42 physician validated exacerbations of COPD with no missing remote monitoring data were documented in 39 patients at a general hospital. Continuous 24-hour monitoring of vital signs using a connected wristband was well accepted over the long term, with a median adherence of 86% indicating strong patient compliance. The BVS3 risk score achieved excellent predictive performance, with an AUC of 0.88 (95% CI 0.83 - 0.92) for moderate and severe AECOPD combined. The BVS3 score anticipated exacerbations an average of 4.4 ± 3.1 days before clinical confirmation, with an overall accuracy of 84.8% and sensitivity of 74% with 85% specificity. Individual Z-scores for heart rate (z-HR), breathing rate (z-BR) and oxygen saturation (z-SpO2) showed specific predictive capabilities for moderate and severe events, yielding AUCs of 0.83, 0.82 and 0.71 respectively, but with inferior performances compared with the combination of the 3 vital signs Z-scores. These results demonstrate that integrating passive remote monitoring with unsupervised statistical modeling provides a scalable, high-compliance approach to AECOPD detection. The interpretable BVS3 risk score achieves good accuracy and anticipation for AECOPD prediction with minimal patient burden. By enabling earlier intervention, this end-to-end digital solution could significantly improve patient outcomes through proactive disease management.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.